MA47604A - Anticorps anti-pd-1 pour le traitement du cancer du poumon - Google Patents

Anticorps anti-pd-1 pour le traitement du cancer du poumon

Info

Publication number
MA47604A
MA47604A MA047604A MA47604A MA47604A MA 47604 A MA47604 A MA 47604A MA 047604 A MA047604 A MA 047604A MA 47604 A MA47604 A MA 47604A MA 47604 A MA47604 A MA 47604A
Authority
MA
Morocco
Prior art keywords
antibodies
treatment
lung cancer
lung
cancer
Prior art date
Application number
MA047604A
Other languages
English (en)
French (fr)
Inventor
Israel Lowy
Petra Rietschel
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA47604A publication Critical patent/MA47604A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA047604A 2017-02-21 2018-02-20 Anticorps anti-pd-1 pour le traitement du cancer du poumon MA47604A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762461672P 2017-02-21 2017-02-21
US201762595190P 2017-12-06 2017-12-06

Publications (1)

Publication Number Publication Date
MA47604A true MA47604A (fr) 2020-01-01

Family

ID=61628468

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047604A MA47604A (fr) 2017-02-21 2018-02-20 Anticorps anti-pd-1 pour le traitement du cancer du poumon

Country Status (12)

Country Link
US (3) US11292842B2 (cg-RX-API-DMAC7.html)
EP (1) EP3585812A1 (cg-RX-API-DMAC7.html)
JP (4) JP7324710B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240011262A (cg-RX-API-DMAC7.html)
CN (2) CN110536905B (cg-RX-API-DMAC7.html)
AU (2) AU2018225102B2 (cg-RX-API-DMAC7.html)
CA (1) CA3054289A1 (cg-RX-API-DMAC7.html)
IL (3) IL268479B2 (cg-RX-API-DMAC7.html)
MA (1) MA47604A (cg-RX-API-DMAC7.html)
MX (2) MX2019009772A (cg-RX-API-DMAC7.html)
WO (1) WO2018156494A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201905051B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160053301A1 (en) 2014-08-22 2016-02-25 Clearfork Bioscience, Inc. Methods for quantitative genetic analysis of cell free dna
US11008391B2 (en) 2015-08-11 2021-05-18 WuXi Biologics Ireland Limited Anti-PD-1 antibodies
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
IL268479B2 (en) * 2017-02-21 2024-06-01 Regeneron Pharma Anti-PD-1 antibodies for the treatment of lung cancer
CN111526886A (zh) * 2017-10-27 2020-08-11 国家血清研究所 多基因流感疫苗
WO2020061376A2 (en) 2018-09-19 2020-03-26 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
WO2020102375A1 (en) 2018-11-14 2020-05-22 Regeneron Pharmaceuticals, Inc. Intralesional administration of pd-1 inhibitors for treating skin cancer
AU2020211584A1 (en) * 2019-01-21 2021-08-26 Sanofi Therapeutic RNA for advanced stage solid tumor cancers
AU2020228296B2 (en) * 2019-02-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Administration of PD-1 inhibitors for treating skin cancer
CN113677707A (zh) 2019-03-06 2021-11-19 瑞泽恩制药公司 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
US20230054413A1 (en) * 2019-12-13 2023-02-23 Samsung Bioepis Co., Ltd. Stable anti-pd1 antibody pharmaceutical formulations
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
DK4117667T3 (da) * 2020-03-13 2025-02-10 Univ Texas Sekventiel behandling af kræft ved hjælp af 6-thio-dg og checkpointhæmmere
CN119255817A (zh) * 2022-03-28 2025-01-03 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
EP4598960A1 (en) * 2022-10-05 2025-08-13 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)
WO2025030110A1 (en) * 2023-08-02 2025-02-06 Sensei Biotherapeutics, Inc. Cancer therapies targeting vista as monotherapy or in combination with anti-pd1 antibody to treat cancer
WO2025159618A1 (ko) 2024-01-24 2025-07-31 주식회사 엘지에너지솔루션 전극탭 용접장치 및 전극탭 용접방법
WO2025207705A1 (en) 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025213154A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
IN2012DN01920A (cg-RX-API-DMAC7.html) 2009-09-03 2015-07-24 Schering Corp
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
HK1207655A1 (en) 2012-05-04 2016-02-05 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
US9889982B2 (en) 2012-07-23 2018-02-13 Silgan Dispensing Systems Corporation Aerosol actuators, devices, and methods of making and using the same
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2015030929A1 (en) 2013-08-30 2015-03-05 Ebay, Inc. Keyword bid optimization for text ads
WO2015088930A1 (en) 2013-12-10 2015-06-18 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
CN106029696B (zh) 2013-12-17 2020-07-28 基因泰克公司 抗cd3抗体及使用方法
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
BR112016029650A2 (pt) 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
US20170326234A1 (en) * 2014-12-02 2017-11-16 Celgene Corporation Combination therapies
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
DK3283107T3 (da) * 2015-04-17 2020-08-31 Bristol Myers Squibb Co Sammensætninger omfattende en kombination af ipilimumab og nivolumab
AU2016262074A1 (en) * 2015-05-12 2017-11-09 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US20180155429A1 (en) * 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
EP3420000A1 (en) 2016-02-25 2019-01-02 Cell Medica Switzerland AG Modified cells for immunotherapy
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
IL268479B2 (en) * 2017-02-21 2024-06-01 Regeneron Pharma Anti-PD-1 antibodies for the treatment of lung cancer
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2023356866A1 (en) * 2022-10-03 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies

Also Published As

Publication number Publication date
CN110536905A (zh) 2019-12-03
AU2018225102A1 (en) 2019-09-05
MX2024000780A (es) 2024-02-06
IL268479B1 (en) 2024-02-01
RU2019129506A (ru) 2021-03-23
IL308805B2 (en) 2025-12-01
IL308805B1 (en) 2025-08-01
KR20240011262A (ko) 2024-01-25
IL268479B2 (en) 2024-06-01
AU2018225102B2 (en) 2024-11-14
CN110536905B (zh) 2023-10-27
US20240209090A1 (en) 2024-06-27
JP2022078265A (ja) 2022-05-24
RU2019129506A3 (cg-RX-API-DMAC7.html) 2021-07-02
IL321717A (en) 2025-08-01
JP2025098103A (ja) 2025-07-01
JP7324710B2 (ja) 2023-08-10
JP2024016192A (ja) 2024-02-06
CA3054289A1 (en) 2018-08-30
JP7656012B2 (ja) 2025-04-02
JP7384949B2 (ja) 2023-11-21
CN117442719A (zh) 2024-01-26
IL308805A (en) 2024-01-01
ZA201905051B (en) 2025-06-25
US11292842B2 (en) 2022-04-05
US11926668B2 (en) 2024-03-12
JP2020508317A (ja) 2020-03-19
KR102628557B1 (ko) 2024-01-29
AU2025201018A1 (en) 2025-03-06
US20220281979A1 (en) 2022-09-08
WO2018156494A1 (en) 2018-08-30
MX2019009772A (es) 2019-12-02
US20200010550A1 (en) 2020-01-09
EP3585812A1 (en) 2020-01-01
KR20190120792A (ko) 2019-10-24
IL268479A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
FR25C1001I1 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
EP3397963A4 (en) P38 MAPK INHIBITION FOR THE TREATMENT OF CANCER
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP3448875A4 (en) Compositions for the treatment of disease
EP3436002A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
EP3432927A4 (en) TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
EP3452060A4 (en) Combination therapy for cancer treatment
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3400010A4 (en) ANTI-HER2 COMBINATIONS FOR THE TREATMENT OF TUMORS
EP3383497A4 (en) NOVEL ANTIBODIES FOR THE TREATMENT OF CANCER DISEASES
EP3389645A4 (en) COMBINATIONS FOR TREATING CANCER
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
EP3359255A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP3541417A4 (en) Combination immunotherapies for treatment of cancer
EP3331510A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP3766497A4 (en) Drug for treating cough